The objectives of the ‘Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS Manifestations’ were to assess the clinical utility of the international consensus statement on classification criteria and treatment guidelines for the catastrophic APS, to identify and grade the studies that analyze the relationship between the antiphospholipid antibodies and the non-criteria APS manifestations, and to present the current evidence regarding the accuracy of these non-criteria APS manifestations for the detection of patients with APS. This article summarizes the studies analyzed on thrombocytopenia and skin manifestations, and presents the recommendations elaborated by the Task Force after this analysis.
AshersonRACerveraRShepshelovichDShoenfeldY. Nonthrombotic manifestations of the antiphospholipid syndrome: away from thrombosis?J Rheumatol2006; 33: 1038–1044.
AshersonRAKhamashtaMAOrdi-RosJ. The “primary” antiphospholipid syndrome: major clinical and serological features. Medicine1989; 68: 366–374.
4.
Mackworth-YoungCGLoizouSWalportMJ. Primary antiphospholipid syndrome: features of patients with raised anticardiolipin antibodies and no other disorder. Ann Rheum Dis1989; 48: 362–367.
5.
CerveraRBoffaMCKhamashtaMAHughesGR. The Euro-Phospholipid project: epidemiology of the antiphospholipid syndrome in Europe. Lupus2009; 18: 889–893.
6.
Alarcón-SegoviaDPérez-VázquezMEVillaARDrenkardCCabiedesJ. Preliminary classification criteria for the antiphospholipid syndrome within systemic lupus erythematosus. Semin Arthritis Rheum1992; 21: 275–286.
7.
Gomez-PuertaJAMartinHAmigoMC. Long-term follow-up in 128 patients with primary antiphospholipid syndrome: do they develop lupus?Medicine (Baltimore)2005; 84: 225–230.
8.
CerveraRPietteJCFontJ. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patients. Arthritis Rheum2002; 46: 1019–1027.
9.
ViannaJLKhamashtaMAOrdi-RosJ. Comparison of the primary and secondary antiphospholipid syndrome: a European multicenter study of 114 patients. Am J Med1994; 96: 3–9.
10.
FontJLopez-SotoACerveraR. The ‘primary’ antiphospholipid syndrome: antiphospholipid antibody pattern and clinical features of a series of 23 patients. Autoimmunity1991; 9: 69–75.
11.
Italian Registry of Antiphospholipid Antibodies. Thrombosis and thrombocytopenia in antiphospholipid syndrome (idiopathic and secondary to SLE): first report from Italian Registry. Haematologica1993; 78: 313–318.
12.
VivancosJLopez-SotoAFontJ. [Primary antiphospholipid syndrome: clinical and biological study of 36 cases]. Med Clin (Barc)1994; 102: 561–565.
13.
CuadradoMJMujicFMunozEKhamashtaMAHughesGR. Thrombocytopenia in the antiphospholipid syndrome. Ann Rheum Dis1997; 56: 194–196.
14.
KrauseIBlankMFraserA. The association of thrombocytopenia with systemic manifestations in the antiphospholipid syndrome. Immunobiology2005; 210: 749–754.
15.
Comellas-KirkerupLHernández-MolinaGCabralAR. Antiphospholipid-associated thrombocytopenia or autoimmune hemolytic anemia in patients with or without definite primary antiphospholipid syndrome according to the Sapporo revised classification criteria: a 6 year follow-up study. Blood2010; 116: 3058–3063.
16.
HarrisENChanJKHAshersonRAAberVRGharaviAEHughesGRV. Thrombosis, recurrent fetal loss and thrombocytopenia. Predictive value of the anticardiolipin antibody test. Arch Intern Med1986; 146: 2153–2156.
17.
HarrisENAshersonRAGharaviAEMorganSHDerueGHughesGRV. Thrombocytopenia in SLE and related autoimmune disorders: association with anticardiolipin antibodies. Br J Haematol1985; 59: 227–230.
18.
KhamashtaMAHarrisENGharaviAE. Immune mediated mechanism for thrombosis: antiphospholipid antibody binding to platelet membranes. Ann Rheum Dis1988; 47: 849–854.
19.
Vázquez-MelladoJLlorenteLRichaud-PatinYAlarcon-SegoviaD. Exposure of anionic phospholipids upon platelet activation permits binding of b2-glycoprotein-I and through it IgG antiphospholipid antibodies. Studies in platelets from patients with antiphospholipid syndrome and normal subjects. J Autoimmunity1994; 7: 335–348.
20.
UthmanIGodeauBTaherAKhamashtaM. The hematologic manifestations of the antiphospholipid syndrome. Blood Rev2008; 22: 187–194.
21.
GalliMDaldossiMBarbuiT. Anti-glycoprotein Ib/IX and IIb/IIIa antibodies in patients with antiphospholipid antibodies. Thromb Haemost1994; 71: 571–575.
22.
GodeauBPietteJCFromontPIntratorLSchaefferABierlingP. Specific antiplatelet glycoprotein autoantibodies are associated with the thrombocytopenia of primary antiphospholipid syndrome. Br J Haematol1997; 98: 873–879.
23.
FabrisFSteffanACordianoI. Specific antiplatelet autoantibodies in patients with antiphospholipid antibodies and thrombocytopenia. Eur J Haematol1994; 53: 232–236.
24.
HashimotoYKawamuraMIchikawaK. Anticardiolipin antibodies in NZW x BXSB F1 mice. A model of antiphospholipid syndrome. J Immunol1992; 149: 1063–1068.
25.
BlankMTincaniAShoenfeldY. Induction of experimental antiphospholipid syndrome in naive mice with purified IgG antiphosphatidylserine antibodies. J Rheumatol1994; 21: 100–104.
26.
BlankMFadenDTincaniA. Immunization with anticardiolipin cofactor (Beta-2-glycoprotein I) induces experimental antiphospholipid syndrome in naive mice. J Autoimmunity1994; 7: 441–455.
27.
OyaizuNYasumizuRMiyama-InabaM. NZW x BXSB)F1 mouse. A new animal model of idiopathic thrombocytopenic purpura. J Exp Med1988; 167: 2017–2022.
28.
MizutaniHEngelmanRWKurataYIkeharaSGoodRA. Development and characterization of monoclonal antiplatelet autoantibodies from autoimmune thrombocytopenic purpura-prone (NZW x BXSB)F1 mice. Blood1993; 82: 837–844.
29.
MonestierMKandiahDAKoutsS. Monoclonal antibodies from NZW x BXSB F1 mice to beta2 glycoprotein I and cardiolipin. Species specificity and charge-dependent binding. J Immunol1996; 156: 2631–2641.
30.
ThiagarajanPLeAShapiroSS. Characterization of beta2-glycoprotein I-dependent and -independent “antiphospholipid” antibodies from lupus-prone NZW/BXSB F1 hybrid male mice. Am J Hematol1997; 56: 86–92.
31.
MiyakisSLockshinMDAtsumiT. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost2006; 4: 295–306.
32.
AtsumiTFurukawaSAmengualOKoikeT. Antiphospholipid antibody associated thrombocytopenia and the paradoxical risk of thrombosis. Lupus2005; 14: 499–504.
33.
StasiRStipaEMasiM. Prevalence and clinical significance of elevated antiphospholipid antibodies in patients with idiopathic thrombocytopenic purpura. Blood1994; 84: 4203–4208.
34.
Pierrot-DeseillignyDCMichelMKhellafM. Antiphospholipid antibodies in adults with immune thrombocytopenic purpura. Br J Haematol2008; 142: 638–643.
35.
FunauchiMHamadaKEnomotoH. Characteristics of the clinical findings in patients with idiopathic thrombocytopenic purpura who are positive for anti-phospholipid antibodies. Intern Med1997; 36: 882–885.
36.
Diz-KüçükkayaRHacihanefiogluAYenerelM. Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: a prospective cohort study. Blood2001; 98: 1760–1764.
37.
WahlDGGuilleminFde MaistreEPerret-GuillaumeCLecompteTThibautG. Meta-analysis of the risk of venous thrombosis in individuals with antiphospholipid antibodies without underlying autoimmune disease or previous thrombosis. Lupus1998; 7: 15–22.
38.
GalliMFinazziGNorbisFMarchioliRBarbuiT. The risk of thrombosis in patients with lupus anticoagulants is predicted by their specific coagulation profile. Thromb Haemost1999; 81: 695–700.
39.
GinsbergJSWellsPSBrill-EdwardsP. Antiphospholipid antibodies and venous thromboembolism. Blood1995; 86: 3685–3691.
40.
De LaatBPengoVPabingerI. The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemost2009; 7: 1767–1773.
41.
De LaatBDerksenRHWMUrbanusRTde ClerckLS. IgG antibodies that recognize epitope Gly40-Arg43 domain I of b2-glycoprotein I cause LAC, and their presence correlates with thrombosis. Blood2005; 105: 1540–1545.
42.
De LaatHBDerksenRHUrbanusRTRoestMde GrootPG. beta2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome. Blood2004; 104: 3598–3602.
ArforsLWiniarskiJLefvertAK. Prevalence of antibodies to cardiolipin in chronic ITP and reactivity with platelet membranes. Eur J Haematol1996; 56: 230–234.
45.
LippEvonFASaxHMullerDBerchtoldP. Antibodies against platelet glycoproteins and antiphospholipid antibodies in autoimmune thrombocytopenia. Eur J Haematol1998; 60: 283–288.
46.
BidotCJJyWHorstmanLL. Antiphospholipid antibodies in immune thrombocytopenic purpura tend to emerge in exacerbation and decline in remission. Br J Haematol2005; 128: 366–372.
47.
AshersonRACerveraR. Microvascular and microangiopathic antiphospholipid-associated syndromes (“MAPS”): semantic or antisemantic?Autoimmun Rev2008; 7: 164–167.
FrancesCNiangSLaffitteEPelletierFCostedoatNPietteJC. Dermatologic manifestations of the antiphospholipid syndrome: two hundred consecutive cases. Arthritis Rheum2005; 52: 1785–1793.
HughesGR. Hughes syndrome–the syndrome behind the name (otherwise known as antiphospholipid syndrome). Isr Med Assoc J1999; 1: 100–103.
53.
KesterSMcCartyDLMcCartyGA. The antiphospholipid antibody syndrome in the emergency department setting–livedo reticularis and recurrent venous thrombosis. Ann Emerg Med1992; 21: 207–211.
54.
ToubiEKrauseIFraserA. Livedo reticularis is a marker for predicting multi-system thrombosis in antiphospholipid syndrome. Clin Exp Rheumatol2005; 23: 499–504.
55.
AshersonRAMayouSCMerryPBlackMMHughesGR. The spectrum of livedo reticularis and anticardiolipin antibodies. Br J Dermatol1989; 120: 215–221.
56.
WeinsteinSPietteW. Cutaneous manifestations of antiphospholipid antibody syndrome. Hematol Oncol Clin North Am2008; 22: 67–77, vi.
57.
DiogenesMJDiogenesPCde Morais CarneiroRMNetoCCDuarteFBHolandaRR. Cutaneous manifestations associated with antiphospholipid antibodies. Int J Dermatol2004; 43: 632–637.
58.
BiggioggeroMMeroniPL. The geoepidemiology of the antiphospholipid antibody syndrome. Autoimmun Rev2010; 9: A299–304.
59.
NaldiLLocatiFMarchesiL. Cutaneous manifestations associated with antiphospholipid antibodies in patients with suspected primary antiphospholipid syndrome: a case-control study. Ann Rheum Dis1993; 52: 219–222.
60.
SebastianiGDGaleazziMTincaniA. Anticardiolipin and anti-beta2GPI antibodies in a large series of European patients with systemic lupus erythematosus. Prevalence and clinical associations. European Concerted Action on the Immunogenetics of SLE. Scand J Rheumatol1999; 28: 344–351.
61.
VlachoyiannopoulosPGKrilisSAHuntJEManoussakisMNMoutsopoulosHM. Patients with anticardiolipin antibodies with and without antiphospholipid syndrome: their clinical features and beta 2-glycoprotein-I plasma levels. Eur J Clin Invest1992; 22: 482–487.
62.
GibsonGESuWPPittelkowMR. Antiphospholipid syndrome and the skin. J Am Acad Dermatol1997; 36: 970–982.
63.
UthmanIWKhamashtaMA. Livedo racemosa: a striking dermatological sign for the antiphospholipid syndrome. J Rheumatol2006; 33: 2379–2382.
64.
FrancesCPapoTWechslerBLaporteJLBiousseVPietteJC. Sneddon syndrome with or without antiphospholipid antibodies. A comparative study in 46 patients. Medicine (Baltimore)1999; 78: 209–219.
65.
DevosJBulckeJDegreefHMichielsenB. Sneddon’s syndrome: generalized livedo reticularis and cerebrovascular disease. Importance of hemostatic screening. Dermatology1992; 185: 296–299.
KraemerMLindenDBerlitP. The spectrum of differential diagnosis in neurological patients with livedo reticularis and livedo racemosa. A literature review. J Neurol2005; 252: 1155–1166.
68.
AclandKMDarvayAWakelinSHRussell-JonesR. Livedoid vasculitis: a manifestation of the antiphospholipid syndrome?Br J Dermatol1999; 140: 131–135.
69.
RossiniJRoveranoSGrafCPairaS. Widespread cutaneous necrosis associated with antiphospholipid antibodies: report of four cases. J Clin Rheumatol2002; 8: 326–331.
70.
AshersonRACerveraRShoenfeldY. Peripheral vascular occlusions leading to gangrene and amputations in antiphospholipid antibody positive patients. Ann N Y Acad Sci2007; 1108: 515–529.
71.
AshersonRACerveraRKlumbE. Amputation of digits or limbs in patients with antiphospholipid syndrome. Semin Arthritis Rheum2008; 38: 124–131.
72.
PascualJCGimenezESiveraFMartinezA. Atrophic macules and soft papules in a 24-year-old woman. Anetoderma associated with antiphospholipid antibodies. Arch Dermatol2007; 143: 109–114.
73.
SparsaAPietteJCWechslerBAmouraZFrancesC. Anetoderma and its prothrombotic abnormalities. J Am Acad Dermatol2003; 49: 1008–1012.
